Literature DB >> 8178687

Epidemiology of psychiatric disorders in Edmonton. Antisocial personality disorders.

M C Swanson1, R C Bland, S C Newman.   

Abstract

3258 randomly selected adult household residents of Edmonton, Canada, were interviewed by trained lay interviewers using the Diagnostic Interview Schedule (DIS). 104 subjects fulfilled DSM-III antisocial personality disorder (ASP) criteria. Lifetime prevalence rates were found to be significantly higher in males and in the younger adult age groups. The age of onset (i.e. age at which conduct disorder symptoms first appeared) was found to be under 10 years in the majority of cases, with females lagging just slightly behind males. Symptom patterns and frequencies were examined and the relative risks for these symptoms were calculated. Comorbidity, calculated using full DSM-III severity criteria, but without exclusion criteria, revealed an increased prevalence of nearly every other psychiatric disorder in those with antisocial personality disorder, with 90.4% having at least one other lifetime psychiatric diagnosis.

Entities:  

Mesh:

Year:  1994        PMID: 8178687

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  16 in total

1.  Categorical and continuous models of liability to externalizing disorders: a direct comparison in NESARC.

Authors:  Kristian E Markon; Robert F Krueger
Journal:  Arch Gen Psychiatry       Date:  2005-12

Review 2.  Why are programmes for offenders with personality disorder not informed by the relevant scientific findings?

Authors:  Conor Duggan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-08-12       Impact factor: 6.237

3.  Antisocial behavioral syndromes and 3-year quality-of-life outcomes in United States adults.

Authors:  R B Goldstein; D A Dawson; S M Smith; B F Grant
Journal:  Acta Psychiatr Scand       Date:  2012-02-29       Impact factor: 6.392

Review 4.  Pharmacological interventions for antisocial personality disorder.

Authors:  Najat Khalifa; Conor Duggan; Jutta Stoffers; Nick Huband; Birgit A Völlm; Michael Ferriter; Klaus Lieb
Journal:  Cochrane Database Syst Rev       Date:  2010-08-04

5.  Sex Differences in Methamphetamine Use and Dependence in a Thai Treatment Center.

Authors:  Teerayuth Rungnirundorn; Viroj Verachai; Joel Gelernter; Robert T Malison; Rasmon Kalayasiri
Journal:  J Addict Med       Date:  2017 Jan/Feb       Impact factor: 3.702

Review 6.  Psychological interventions for antisocial personality disorder.

Authors:  Simon Gibbon; Conor Duggan; Jutta Stoffers; Nick Huband; Birgit A Völlm; Michael Ferriter; Klaus Lieb
Journal:  Cochrane Database Syst Rev       Date:  2010-06-16

7.  Three-year follow-up of syndromal antisocial behavior in adults: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Risë B Goldstein; Bridget F Grant
Journal:  J Clin Psychiatry       Date:  2009-06-16       Impact factor: 4.384

8.  The Epidemiology of Antisocial Behavioral Syndromes in Adulthood: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III.

Authors:  Risë B Goldstein; S Patricia Chou; Tulshi D Saha; Sharon M Smith; Jeesun Jung; Haitao Zhang; Roger P Pickering; W June Ruan; Boji Huang; Bridget F Grant
Journal:  J Clin Psychiatry       Date:  2017-01       Impact factor: 4.384

9.  A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder.

Authors:  Anthony Bateman; Jennifer O'Connell; Nicolas Lorenzini; Tessa Gardner; Peter Fonagy
Journal:  BMC Psychiatry       Date:  2016-08-30       Impact factor: 3.630

10.  Association of monoamine oxidase-A genetic variants and amygdala morphology in violent offenders with antisocial personality disorder and high psychopathic traits.

Authors:  Nathan J Kolla; Raihaan Patel; Jeffrey H Meyer; M Mallar Chakravarty
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.